Carfilzomib

Relapsed Or Refractory Multiple Myeloma, Therapeutic procedure
Treatment
1 FDA approval
20 Active Studies for Carfilzomib

What is Carfilzomib

CarfilzomibThe Generic name of this drug
Treatment SummaryCarfilzomib is an intravenous medication used to treat relapsed or refractory multiple myeloma in adults. It is a modified peptide and an analog of epoxomicin, and works by inhibiting the action of proteasomes. The FDA approved carfilzomib in 2012.
Kyprolisis the brand name
image of different drug pills on a surface
Carfilzomib Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Kyprolis
Carfilzomib
2012
3

Approved as Treatment by the FDA

Carfilzomib, also known as Kyprolis, is approved by the FDA for 1 uses like Relapsed Or Refractory Multiple Myeloma .
Relapsed Or Refractory Multiple Myeloma
Used to treat Relapsed Or Refractory Multiple Myeloma in combination with Dexamethasone

Effectiveness

How Carfilzomib Affects PatientsCarfilzomib is an intravenous drug used to suppress proteasome activity in the blood. After the first dose of 15 or 20 mg/m2, proteasome inhibition was 79-89% and 82-83%, respectively. Additionally, the drug also inhibited certain subunits of the immunoproteasome, ranging from 26-32% and 41-49% at 20 mg/m2. These effects lasted for at least 48 hours after the first dose. Resistance to carfilzomib has been noted, potentially caused by increased P-glycoprotein levels. Studies indicate that carfilzomib
How Carfilzomib works in the bodyCarfilzomib is made up of four modified peptides and works by blocking the proteasome, a cell component that breaks down proteins. It binds to three active sites within the proteasome, chymotrypsin, trypsin, and caspase-like sites. By blocking these sites, carfilzomib stops cancer cells from reproducing and eventually kills them. At higher doses, it also blocks the trypsin and caspase-like sites.

When to interrupt dosage

The quantity of Carfilzomib is dependent upon the declared state, which may include Refractory Multiple Myeloma, Waldenstrom Macroglobulinemia and Relapsed Or Refractory Multiple Myeloma. The measure of dosage is contingent upon the method of delivery (e.g. Injection, powder, lyophilized, for solution or Powder, for solution - Intravenous) specified in the ensuing table.
Condition
Dosage
Administration
Relapsed Or Refractory Multiple Myeloma
6.0 mg/mL, , 3.0 mg/mL, 60.0 mg, 30.0 mg, 10.0 mg, 10.0 mg/mL
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution
Therapeutic procedure
6.0 mg/mL, , 3.0 mg/mL, 60.0 mg, 30.0 mg, 10.0 mg, 10.0 mg/mL
, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Warnings

There are 20 known major drug interactions with Carfilzomib.
Common Carfilzomib Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Carfilzomib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Carfilzomib.
Acteoside
Major
The risk or severity of adverse effects can be increased when Carfilzomib is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Carfilzomib is combined with Antilymphocyte immunoglobulin (horse).
Axitinib
Major
The serum concentration of Axitinib can be increased when it is combined with Carfilzomib.
Carfilzomib Toxicity & Overdose RiskCommon side effects of this drug include tiredness, low red blood cell count, nausea, low platelet count, shortness of breath, diarrhea, and fever. The two adverse reactions that are most likely to occur at high doses are low platelet count and fever with a low white blood cell count. The maximum safe dose for this drug is 15 mg/m^2.
image of a doctor in a lab doing drug, clinical research

Carfilzomib Novel Uses: Which Conditions Have a Clinical Trial Featuring Carfilzomib?

49 active trials are ongoing to assess the potential of Carfilzomib in managing Refractory Multiple Myeloma, Waldenstrom Macroglobulinemia and other Therapeutic Procedures.
Condition
Clinical Trials
Trial Phases
Therapeutic procedure
0 Actively Recruiting
Relapsed Or Refractory Multiple Myeloma
22 Actively Recruiting
Phase 1, Phase 2

Carfilzomib Reviews: What are patients saying about Carfilzomib?

5Patient Review
12/9/2013
Carfilzomib for Multiple Myeloma
Carfilzomib was the only treatment that worked for me. I've been on it for two years and it's helped me achieve partial remission.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about carfilzomib

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is carfilzomib used for?

"This medication is used on its own to treat cancer that has come back (relapsed) or did not respond to previous treatment (refractory) multiple myeloma, a type of bone marrow cancer, in patients who have received one or more previous treatments."

Answered by AI

What class of drug is carfilzomib?

"Carfilzomib is a type of medication that inhibits proteasomes. It works by halting or slowing the growth of cancer cells in the body."

Answered by AI

What type of drug is carfilzomib?

"Carfilzomib is a cancer medicine that kills cancer cells by interfering with their growth."

Answered by AI

Is carfilzomib a monoclonal antibody?

"Background: Isatuximab and carfilzomib are both effective at treating relapsed and refractory multiple myeloma."

Answered by AI

Is carfilzomib a chemotherapy drug?

"Kyprolis is a chemotherapy drug that is used to treat multiple myeloma. Kyprolis is a second-generation proteasome inhibitor. Multiple myeloma is a type of blood cancer that affects plasma cells. Plasma cells are found in bone marrow."

Answered by AI

What is another name for carfilzomib?

"Kyprolis is a prescription medicine that is used to treat Multiple myeloma. Kyprolis can be used by itself or with other medications."

Answered by AI

Clinical Trials for Carfilzomib

Have you considered Carfilzomib clinical trials? We made a collection of clinical trials featuring Carfilzomib, we think they might fit your search criteria.
Have you considered Carfilzomib clinical trials? We made a collection of clinical trials featuring Carfilzomib, we think they might fit your search criteria.
Have you considered Carfilzomib clinical trials? We made a collection of clinical trials featuring Carfilzomib, we think they might fit your search criteria.